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Many risk factors exist for chemotherapy-induced nausea and vomiting (CINV). This study utilized a mul-
tivariate projection technique to identify which risk factors were predictive of CINV in clinical practice. A
single-centre, prospective, observational study was conducted from January 2007~July 2010 in Singapore.
Patients were on highly (HECs) and moderately emetogenic chemotherapies with/without radiotherapy.
Patient demographics and CINV risk factors were documented. Daily recording of CINV events was done
using a standardized diary. Principal component (PC) analysis was performed to identify which risk fac-
tors could differentiate patients with and without CINV. A total of 710 patients were recruited. Majority
were females (67%) and Chinese (84%). Five risk factors were potential CINV predictors: histories of
alcohol drinking, chemotherapy-induced nausea, chemotherapy-induced vomiting, fatigue and gender.
Period (ex-/current drinkers) and frequency of drinking (social/chronic drinkers) differentiated the CINV
endpoints in patients on HECs and anthracycline-based, and XELOX regimens, respectively. Fatigue inter-
ference and severity were predictive of CINV in anthracycline-based populations, while the former was
predictive in HEC and XELOX populations. PC analysis is a potential technique in analyzing clinical pop-
ulation data, and can provide clinicians with an insight as to what predictors to look out for in the clinical
assessment of CINV. We hope that our results will increase the awareness among clinician-scientists
regarding the usefulness of this technique in the analysis of clinical data, so that appropriate preventive
measures can be taken to improve patients' quality of life.
Key words: Chemotherapy-induced nausea and vomiting, Multivariate projection, Principal component
analysis, Principal variables, Risk factors
INTRODUCTION
Patients who are on certain chemotherapies tend to suffer
from certain adverse drug reactions, of which chemother-
apy-induced nausea and vomiting (CINV) are two of the
most distressing (Stieler et al., 2003). The prevalence of
CINV ranges from 13~58% for acute nausea and vomiting
(NV lasting up to 24 hours after chemotherapy), and 15~
75% for delayed nausea and vomiting (NV occurring after
24 hours and lasting up to 5 to 7 days) (Booth et al., 2007;
Cohen et al., 2007; Erazo Valle et al., 2006; Grunberg et al.,
2004; Liau et al., 2005; Molassiotis et al., 2008). CINV
causes extreme discomfort in patients with cancer and can
also lead to a decrease in their quality of life, despite pre-
ventive therapies with antiemetics (Bloechl-Daum et al.,
2006; Roscoe et al., 2010; Schnell, 2003).
CINV is a complicated condition that is affected by many
factors, including emetogenicity of chemotherapy regimens
(CRegs) and patient-related factors (e.g. young age, female
gender, prior CINV experiences, histories of morning and
motion sickness, low alcohol use, and presence of anxiety,
fatigue and labyrinthitis) (Hesketh, 1999; Lohr, 2008;
Molassiotis et al., 2002; National Comprehensive Cancer
Network, c2011; Pollera and Giannarelli, 1989; Roscoe et
al., 2010; Shih et al., 2009). Some risk factors, such as anx-
iety and fatigue, are subjective in nature and difficult to
quantify. Furthermore, the methodologies of assessing cer-
tain risk factors and their evidence as clinical predictors for
CINV have been inconsistent. Clinicians need appropriate
measures so as to better assess their patients’ risks of CINV
in daily practice.
Informatics and information technology (IT) have gained
increasing acceptance and are becoming extremely popular
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among healthcare professionals. However, the adoption of
IT to improve the pharmaceutical care of patients with can-
cer has been slow. Recently, a multivariate projection tech-
nique, known as principal component (PC) analysis, has
been employed to investigate the relationships among mul-
tiple variables for various medical purposes, such as in the
interpretation of repetitive nerve stimulation results (Cen-
giz and Kuruo lu, 2006). This technique has also become
popular in studies dealing with cancer, such as evaluating
various symptom clusters in patients suffering from brain
and bone metastases (Chow et al., 2008; Hadi et al., 2008).
The principle of PC analysis is to linearly transform an
original set of variables into a substantially smaller set of
uncorrelated variables that represent most of the informa-
tion in the original dataset (Dunteman, 1989). Many risk
factors that predispose patients to CINV have been identi-
fied in the literature, but a large combination of these risk
factors have not been studied to identify the ones that play a
more important role in patients manifesting this chemother-
apy-induced toxicity. PC analysis is well-suited for this pur-
pose, since it reduces the number of variables (CINV risk
factors in this case) to only those that explain majority of
the variation in the dataset (Asian cancer patients). There-
fore, the objective of our study was to utilize this technique
to determine which of the treatment-related and patient-
related risk factors could be clinically useful for the predic-
tion of CINV in the practice setting.
MATERIALS AND METHODS
Study design and setting. A single-centre, prospec-
tive, observational study was conducted between January
g
⌒
Table 1. Chemotherapy regimens and antiemetics received by patients in the study
Type of regimen Regimen protocol Regimen details Antiemetics prescribeda,b
Breast cancer
regimens
AC Intravenous Doxorubicin 60 mg/m
2/day,
Intravenous Cyclophosphamide 600 mg/m2/day
Acute antiemetics:
Intravenous Granisetron 3 mg, Intravenous 
Dexamethasone 8 mg
Delayed antiemetics:
Oral Granisetron 1 mg/day, Oral Dexametha-
sone 4 mg twice daily
FAC 
Intravenous Doxorubicin 50 mg/m2/day,
Intravenous Cyclophosphamide 500 mg/m2/day,
Intravenous Fluorouracil 500 mg/m2/day
FEC (500/
100/500)
Intravenous Epirubicin 100 mg/m2/day,
Intravenous Cyclophosphamide 500 mg/m2/day,
Intravenous Fluorouracil 500 mg/m2/day
FEC (500/
75/500)
Intravenous Epirubicin 75 mg/m2/day,
Intravenous Cyclophosphamide 500 mg/m2/day,
Intravenous Fluorouracil 500 mg/m2/day
Gastro-intestinal
cancers
XELOX Intravenous Oxaliplatin 130 mg/m
2/day,
Oral Capecitabine 2000 mg/m2/day
Acute antiemetics:
Intravenous Ondansetron 8 mg, Intravenous 
Dexamethasone 8mg
Delayed antiemetics:
Oral Ondansetron 8 mg/day, Oral Dexametha-
sone 4 mg twice daily
Head and neck
cancers
CDDP 40 Intravenous Cisplatin 40 mg/m2/day
Acute antiemetics:
Intravenous Granisetron 3 mg, Intravenous 
Dexamethasone 8 mg
Delayed antiemetics:
Oral Granisetron 1 mg/day, Oral Dexametha-
sone 4 mg twice daily
CDDP 100 Intravenous Cisplatin 100 mg/m2/day
Acute antiemetics:
Oral Aprepitant 125 mg, Intravenous Granis-
etron 3 mg, Intravenous Dexamethasone 8 mg
Delayed antiemetics:
Oral Aprepitant 80 mg/day (days 2~3), Oral 
Dexamethasone 4 mg twice daily
 PF (80/1000)
Intravenous Cisplatin 20 mg/m2/day,
Intravenous Fluorouracil 1000 mg/m2/day,
for 4 days
Acute antiemetics:
Intravenous Granisetron 3 mg (days 1~4), Intra-
venous Dexamethasone 8 mg (days 1~4)
Delayed antiemetics:
Oral Dexamethasone 4 mg twice daily (days 
5~9)
aAcute antiemetics were given on the day of chemotherapy (day 1), while delayed antiemetics were given on days 2~4, unless stated otherwise.
bOral metoclopramide 20 mg was prescribed up to 4 times daily when needed as rescue therapy.
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2007 and July 2010 at the ambulatory treatment unit of the
National Cancer Centre, Singapore (NCCS). Inclusion crite-
ria were patients at least 21 years of age with confirmed
diagnoses of breast, head and neck, and gastrointestinal
cancers. Exclusion criteria were the inability to understand
English or Mandarin, and those who refused follow-up for
the duration of the study. Patients were on a variety of eme-
togenic single-day or multiple-day chemotherapy protocols
with/without radiotherapy (Table 1) and appropriate anti-
emetics. This study was approved by the NCCS’s institu-
tional review board and written informed consent was
obtained from all patients prior to participation in the study.
Procedures and instruments for data collection.
Patients were interviewed on their first day of chemother-
apy to document their demographics, CINV risk factors
(Table 2) and dispensed antiemetics. Patients’ anxiety char-
acteristics were evaluated using the Beck Anxiety Inven-
tory (BAI) (Beck et al., 1988), a 21-item instrument for
assessing the severity of various anxiety symptoms. This
instrument has a high internal consistency of 0.92 and test-
retest reliability of 0.75, and was also validated in the local
population (Luo et al., 2004).
A standardized self-administered CINV diary was given
to patients to record their daily number of vomiting events
and intensity of nausea after chemotherapy, and use of anti-
emetics. Patients on single-day regimens and the multiple-day
regimen (PF) completed a 5-day and 9-day diary respec-
tively. Nausea intensity was measured using a 0 to 10 Likert
scale in order of increasing intensity. Patients also docu-
mented the antiemetics and the periods of the day (morning,
afternoon, evening, night) in which they took for delayed
and breakthrough CINV. A telephone interview was con-
ducted after diary completion for documentation of their
CINV responses. The study design is summarized in Fig. 1.
Definitions of CINV responses. A patient was consid-
ered to have acute vomiting or nausea respectively if at
least one vomiting episode or nausea scores greater than or
equal to 1 (on a scale of 0~10) was reported on day 1 of sin-
gle-day chemotherapies and days 1~4 of multi-day chemo-
therapies. These parameters were similarly defined for
delayed vomiting or nausea if these occurred any day after
the first day of chemotherapy (days 2~5 for single-day regi-
mens, days 5~9 for multi-day regimens). A vomiting epi-
sode was defined as a single vomit or retch, or any number
of continuous vomits or retches, separated from each other
for at least 1 minute. A number of other parameters, referred
to as clinical or CINV endpoints, were also employed (Arporn-
wirat et al., 2009; Gralla et al., 2005; Herrstedt et al., 2009;
Hesketh et al., 2009; Jordan et al., 2009; Mueller et al.,
2009; Yeo et al., 2009): (a) complete response (CR: no
vomiting and no rescue antiemetics), (b) complete protec-
tion (CP: no vomiting, no significant nausea (scores 0~2)
and no rescue antiemetics), and (c) complete control (CC:
no vomiting, no nausea (score 0), and no rescue antiemetics).
Antiemetic treatment. Antiemetic management was
regulated by a guideline established by the NCCS Phar-
macy and Therapeutics Committee whereby standardized
prophylactic antiemetic regimens comprising of a neuroki-
nin-1 antagonist, serotonin antagonist and dexamethasone
were given to patients for prevention of acute and delayed
CINV (Table 1). At the NCCS, aprepitant-based antiemetic
Table 2. List of risk factors analyzed in the study population
Risk factors Parameters analyzed
Age Less than 50 years old/equal to or greater than 50 years old
Anxiety Scores of anxiety symptoms based on the Beck Anxiety Inventory
Concurrent radiotherapy Presence/absence
Earache/ringing in the ears Presence/absence before the initiation of chemotherapy
Emetogenicity of chemotherapy Low/moderate/high
Fatigue/tiredness a) Fatigue interference: Degree in which fatigue interferes with the patient’s ability to engage in
daily activities (since time of cancer diagnosis or the last 6 months, whichever is shorter)
b) Fatigue severity: Degree of fatigue severity that the patient is experiencing at the time of
survey administration
Both parameters were analyzed based on a Likert scale of 0 to 10
Gender Female/male
History of alcohol use a) Non-drinker (or drank negligible amounts of alcohol throughout lifetime)/drinker
b) Period of drinking: Ex-drinker/current drinker
c) Frequency of drinking: Social drinker (< 1 drink/day)/chronic drinker (≥ 1 drink/day)
Histories of chemotherapy-induced
nausea and vomiting (where applicable)
a) Nausea: None/mild/moderate/severe
b) Vomiting: None/mild/moderate/severe
History of morning sickness
(where applicable)
Presence/absence
History of motion sickness Presence/absence
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regimens would only be recommended as first-line prophy-
laxis for high-dose cisplatin-based CRegs. However, the
aprepitant-based antiemetic regimen could also be prescribed
based on risk factor assessments by oncology clinicians (e.g.,
poor control of CINV in the previous chemotherapy cycle).
A four-day supply (30 tablets) of the dopamine antagonist,
metoclopramide, was also given to patients as rescue ther-
apy for breakthrough emesis, to be taken when needed.
Data analyses. Descriptive statistics were used to sum-
marize patient demographics and CINV characteristics. PC
analysis was performed to analyze the various risk factors.
Fig. 1. Summary of the study design.
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For illustrative purposes and easy understanding by clini-
cians who may otherwise not be familiar with this multi-
variate projection technique, the following describes the
concept of how PC analysis can be applied to clinical
patient populations (Fig. 2). In this study, every CINV risk
factor (also known as a variable) can be plotted for the
patient samples. For ‘n’ variables, the patients can be plot-
ted in ‘n-dimensional’ space. PC analysis reduces the data
into a subset of variables that can represent most of the vari-
ation in the total dataset (i.e. the overall risk of experienc-
ing CINV). To simplify this concept, let’s use 3 variables
(e.g. histories of alcohol drinking, chemotherapy-induced
nausea, and vomiting) to represent the overall CINV risks
of the patients. As shown in Fig. 2, each patient can be plot-
ted in 3-dimensional space based on the PC scores of the
variables. The plotted data is centered so that it varies
around zero. A hypothetical line of best fit (known as a PC)
can be drawn in the 3-dimensional space to explain the vari-
ation in the whole set of data. PC1 (dotted and dashed line)
gives the direction of maximum variance, while PC2 (dashed
line) is at right angles to PC1 and oriented to the direction
which gives the maximum remaining variability. In turn,
PC3 (solid line) is at right angles to both PCs 1 and 2. This
reiterative process goes on for the remaining PCs until the
rest of the variability in the data is explained. It is impor-
tant to note that all the PCs have a common origin of cen-
tered data, and since the PCs are perpendicular to each
other, the variables are uncorrelated. In this study, the eigen-
vectors (or weightage) of the variables (i.e. risk factors)
were used to interpret the PC data based on decomposition
of the correlation matrix. The number of PCs selected was
based on a combination of Jolliffe’s eigenvalue cut-off,
Catell’s scree plot and an 80% variance cut-off.
A subset of the variables, known as principal variables
(PVs), was used to represent the variation in the dataset.
These PVs were represented by the risk factors that had the
highest weightings on its corresponding PC, and were iden-
tified for patients with and without the clinical endpoints
(CR, CP and CC). From this subset, those PVs that could
distinguish patients with and without CINV were deter-
mined. PVs exhibited by the former group of patients (i.e.
those who did not achieve the clinical endpoints), but not by
the latter group, were identified as potential clinical CINV
predictors. The percentage contributions of these clinical
predictors to their PCs were compiled together with their
direction cosines, which were reflective of the correlations
between their PCs and symptom axes. A value closer to 1
would mean a greater correlation between the PC and that
particular predictor. The software programmes StatistiXL
v1.8 (StatistiXL, Nedlands, Western Australia) and XLStat
v2010.6.01 (Addinsoft, New York, NY) were used for PC
analysis and SPSS v17.0 (SPSS Inc., Chicago, IL) was used
to calculate the descriptive statistics.
RESULTS
Demographics and CINV characteristics of patients.
A total of 1027 patients were approached, of which 233
patients (23%) rejected participation in the study and 84
patients (8%) were either lost to follow up or handed in
incomplete CINV diaries. The resultant number of recruited
patients was 710 (69%). Among these, 139 (20%) were on
highly-emetogenic chemotherapies (HECs), 361 (51%) were
on anthracycline-based (AC-based) regimens and 210 (30%)
were on XELOX regimens.
Mean age of the patients was 52.9 ± 10.3 years, with
majority (63%) being over 50 years of age (Table 3). More
than half (67%) were females. This was due to the percent-
age skew of females on AC-based regimens (99.7%). In
contrast, females explained only 21% and 42% of the
patients on HECs and XELOX regimens respectively. Most
patients were Chinese (84%), married (80%) and of a sec-
ondary school education (42%).
Generally, most patients suffered from delayed CINV;
with triple the proportion suffering from delayed nausea
Fig. 2. Illustration of how PC analysis was applied in this study.
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(67%) than vomiting (22%). A decreasing trend was observed
in patient proportions that achieved the endpoints of CR
(58%), CP (42%) and CC (27%). This trend occurred for
both the acute and delayed responses, as well as among the
various categories of CRegs. Patients on XELOX achieved
the highest CINV endpoints (CR, CP and CC), which was
Table 3. Demographics and CINV characteristics of patients
Patient demographics
Number of patients in
all regimens (%)a,
n = 710
Number of patients in
HEC regimens (%)a,
n = 139
Number of patients in
AC-based regimens (%)a,
n = 361
Number of patients in
XELOX regimens (%)a,
n = 210
Age (years)
< 30 08 (1) 04 (3) 002 (1) 02 (1)
30~39 61 (9) 019 (14) 041 (11) 01 (1)
40~49 195 (28) 046 (33) 130 (36) 19 (9)
50~59 266 (38) 046 (33) 138 (38) 082 (39)
≥ 60 180 (25) 024 (17) 050 (14) 106 (51)
Race
Chinese 593 (84) 114 (82) 293 (81) 186 (89)
Malay 072 (10) 015 (11) 043 (12) 14 (7)
Indian 23 (3) 03 (2) 014 (4) 06 (3)
Others 22 (3) 07 (5) 011 (3) 04 (2)
Gender
Male 233 (33) 110 (79) 001 (0.3) 122 (58)
Female 477 (67) 029 (21) 360 (99.7) 088 (42)
Marital status
Single 094 (13) 017 (12) 056 (16) 021 (10)
Married 571 (80) 121 (87) 278 (77) 172 (82)
Divorced 13 (2) 00 (0) 007 (2) 06 (3)
Widowed 19 (3) 01 (1) 007 (2) 11 (5)
Highest education level
No education 34 (5) 00 (0) 019 (5) 15 (7)
Primary 185 (26) 030 (22) 091 (25) 064 (31)
Secondary 295 (42) 060 (43) 151 (42) 084 (40)
Pre-university 118 (17) 026 (19) 061 (17) 031 (15)
Graduate 56 (8) 016 (12) 030 (8) 10 (5)
Postgraduate 22 (3) 07 (5) 009 (3) 06 (3)
CINV characteristics Number of patients in
all regimens (%)b
Number of patients in
HEC regimens (%)b
Number of patients in
AC-based regimens (%)b
Number of patients in
XELOX regimens (%)b
Chemotherapy-induced nausea
Acute 387 (55) 075 (54) 240 (67) 072 (34)
Delayed 472 (67) 090 (65) 278 (77) 104 (50)
Chemotherapy-induced vomiting
Acute 103 (15) 016 (12) 77 (21) 10 (5)
Delayed 156 (22) 035 (25) 89 (25) 032 (15)
Complete response (CR)
Acute 537 (76) 110 (79) 243 (67) 184 (88)
Delayed 450 (63) 077 (55) 213 (59) 160 (76)
Overall 409 (58) 070 (50) 182 (50) 157 (75)
Complete protection (CP)
Acute 428 (60) 089 (64) 173 (48) 166 (79)
Delayed 325 (46) 058 (42) 129 (36) 138 (66)
Overall 297 (42) 051 (37) 113 (31) 133 (63)
Complete control (CC)
Acute 308 (43) 062 (45) 112 (31) 134 (64)
Delayed 219 (31) 043 (31) 075 (21) 101 (48)
Overall 194 (27) 035 (25) 062 (17) 097 (46)
aPercentages may not add to 100% due to missing data and rounding of figures.
bPercentages may be over 100% due to patients suffering from multiple effects.
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Table 4. Risk factors identified as principal variables for the prediction of clinical CINV endpoints
Clinical CINV endpoints Risk factors identified as principal variables
Overall patient
population (n = 710)
Patients on HEC
regimens (n = 139)
Patients on AC-based
regimens (n = 361)
Patients on XELOX
regimens (n = 210)
Overall complete 
response (CR)
• Fatigue 
interference (PC4)
• Ex-/current drinkers 
(PC1)
• History of chemotherapy-
induced vomiting (PC1)
• Gender (PC4)
-- • Social/chronic drinkers 
(PC1)
• History of chemotherapy-
induced nausea (PC2)
• Fatigue interference (PC3)
Overall complete 
protection (CP)
-- • Ex-/current drinkers 
(PC1)
• Fatigue severity 
(PC4)
• Fatigue interference (PC3)
Overall complete 
control (CC)
-- • Ex-/current drinkers 
(PC1)
• Fatigue interference 
(PC3)
• Fatigue severity (PC4)
• Fatigue severity 
(PC4)
--
CR: No vomiting and no rescue antiemetics
CP: No vomiting, no significant nausea and no rescue antiemetics
CC: No vomiting, no nausea and no rescue antiemetics
Table 5. Clinical predictors of CINV identified in the study population (nall = 710, nHEC = 139, nAC-based = 361, nXELOX = 210)
Risk factor
Variation in patients with regards to
complete response (CR)
(% variation, eigenvector)
Variation in patients with regards to
complete protection (CP)
(% variation, eigenvector)
Variation in patients with regards to
complete control (CC)
(% variation, eigenvector)
Acute Delayed Overall Acute Delayed Overall Acute Delayed Overall
Ex-/current drinkers
All -- -- -- -- -- -- -- -- --
HEC --
20.8% of 
PC1, 0.421/
-0.421
20.6% of 
PC1, -0.405/ 
0.405
--
22.9% of 
PC1, 0.411/
-0.411
23.0% of 
PC1, 0.399/
-0.399
--
25.0% of 
PC1, -0.423/
0.423*
26.0% of 
PC1, -0.411/
0.411*
AC-based -- -- --
11.8% of 
PC3, 0.538/
-0.538
-- --
12.3% of 
PC3, 0.592/
-0.592
-- --
XELOX
13.7% of 
PC2, 0.543/
-0.543
-- -- -- -- -- -- -- --
Social/chronic drinkers
All
9.6% of
PC4, -0.408/
0.408
-- -- -- -- -- -- -- --
HEC -- -- -- -- -- -- -- -- --
AC-based
17.3% of
PC1, 0.535/
-0.535*
-- -- -- -- -- -- -- --
XELOX --
17.4% of
PC1, 0.458/
-0.458
17.6% of
PC1, 0.459/
-0.459
18.0% of
PC1, -0.426/
0.426
-- -- -- -- --
Non-drinkers
All -- -- -- -- 6.2% ofPC6, 0.534
6.1% of
PC6, 0.588 -- -- --
HEC -- -- -- -- -- -- -- -- --
AC-based -- -- -- -- -- -- -- -- --
XELOX -- -- -- -- -- -- -- -- --
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Table 5. Continued
Risk factor
Variation in patients with regards to
complete response (CR)
(% variation, eigenvector)
Variation in patients with regards to
complete protection (CP)
(% variation, eigenvector)
Variation in patients with regards to
complete control (CC)
(% variation, eigenvector)
Acute Delayed Overall Acute Delayed Overall Acute Delayed Overall
Fatigue interference
All 11.7% ofPC3, 0.440
10.7% of
PC4, 0.389
10.2% of
PC4, 0.484
10.3% of
PC4, 0.495
9.3% of
PC4, 0.379 --
9.7% of
PC4, 0.438 -- --
HEC -- -- -- 10.3% ofPC5, 0.512
10.3% of
PC4, 0.508 -- --
12.5% of
PC3, 0.481
11.8% of
PC3, 0.477
AC-based 5.8% ofPC8, -0.449 -- -- -- -- --
13.4% of
PC2, 0.438 -- --
XELOX -- -- 13.9% ofPC3, 0.454 --
12.2% of
PC3, 0.447
13.4% of
PC3, 0.486
14.9% of
PC2, 0.472 -- --
Fatigue severity
All -- -- -- -- -- -- -- -- --
HEC -- 5.7% ofPC7, 0.547 -- -- -- --
5.4% of
PC8, -0.400
5.9% of
PC8, -0.297
10.3% of
PC4, 0.456
AC-based -- -- -- -- -- 9.2% ofPC4, 0.367 --
9.8% of
PC4, 0.451
9.8% of
PC4, 0.411
XELOX -- -- -- 12.9% ofPC3, 0.436 -- -- -- -- --
Gender
All 17.7% ofPC1, 0.476
17.3% of
PC1, 0.482 --
17.6% of
PC1, 0.449 -- --
16.2% of
PC1, 0.499 -- --
HEC -- -- 10.7% ofPC4, 0.461
11.1% of
PC4, 0.551 -- --
11.4% of
PC4, 0.548
9.8% of
PC5, 0.455 --
AC-based -- -- -- -- -- -- -- -- --
XELOX -- 11.9% ofPC4, 0.477 -- -- -- -- --
11.3% of
PC3, 0.409 --
History of chemotherapy-induced nausea
All -- -- -- -- -- 7.4% ofPC5, 0.434
7.2% of
PC5, 0.479 -- --
HEC -- -- -- -- 4.3% ofPC9, 0.427
4.6% of
PC9, 0.549 --
4.9% of
PC9, 0.483
5.0% of
PC9, 0.442
AC-based -- -- -- 12.7% ofPC3, 0.444
13.2% of
PC3, 0.456 -- --
12.9% of
PC2, 0.430 --
XELOX -- 16.5% ofPC2, 0.427
17.0% of
PC2, 0.433
8.3% of
PC5, 0.547 -- -- -- -- --
History of chemotherapy-induced vomiting
All -- -- -- -- -- -- -- -- 4.5% ofPC10, -0.386
HEC -- 21.6% ofPC1, 0.453
20.5% of
PC1, 0.465 --
20.8% of
PC1, 0.449 -- --
19.2% of
PC1, 0.461 --
AC-based -- -- -- -- 4.9% ofPC10, 0.436 --
12.8% of
PC3, 0.442
4.7% of
PC10, 0.445 --
XELOX -- -- -- 7.9% ofPC6, 0.598 -- -- -- -- --
All: All regimens inclusive of HEC, AC-based and XELOX regimens.
HEC: Highly-emetogenic regimens (CDDP40, CDDP100 and PF regimens).
AC-based: AC-based regimens (AC, FAC and FEC regimens).
XELOX: XELOX regimen.
*Direction cosine is greater than 0.71, therefore the risk factor is closely related to its principal component.
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consistent with the low proportions who suffered from
acute and delayed NV.
Identification of CINV predictors through multivariate
projection of risk factors. Five risk factors played essential
roles in distinguishing the clinical endpoints for patients on
moderately-emetogenic chemotherapies (MECs) and HECs -
histories of alcohol drinking, chemotherapy-induced nausea,
chemotherapy-induced vomiting, fatigue and gender (Table
4). The former 3 risk factors distinguished the clinical end-
points in patients on HECs and XELOX.
Generally, patients who drank less alcohol were more
prone to suffering from CINV. Non-drinkers was a clinical
predictor of patients who did not achieve delayed and over-
all CP (6.1~6.2% of PC6) when the whole patient popula-
tion was taken into account (Table 5). However, the period
of drinking (ex-/current drinkers) was more important than
the frequency of drinking (social/chronic drinkers) when
differentiating the endpoints of patients on CRegs of higher
emetogenicity, such as the HECs (20.6~26.0% of PC1) and
AC-based regimens (11.8~12.3% of PC3). In contrast, the
frequency of drinking (social/chronic drinkers) played a more
essential role for differentiating the endpoints of patients on
CRegs that were less emetogenic (17.4~18.0% of PC1 for
XELOX).
Histories of chemotherapy-induced nausea and chemo-
therapy-induced vomiting played more obvious roles in dis-
tinguishing the endpoints in patients on AC-based and
XELOX regimens, and HECs, respectively. History of
vomiting better distinguished patients without CR for more
highly emetogenic CRegs (20.5~21.6% of PC1), while his-
tory of nausea explained higher variation proportions in
AC-based (12.7% of PC3 - 12.9% of PC2) and XELOX
patients (8.3% of PC5 - 17.0% of PC2).
Generally, fatigue interference was a better predictor of
CINV than fatigue severity in the overall patient popula-
tion. Fatigue interference could distinguish patients without
overall CR across all the CRegs. In fact, its role was of a
higher priority (PC3) compared to fatigue severity (PC4)
when analyzed in the separate CReg categories (Table 4).
Patients on HECs (10.3% of PC5 - 12.5% of PC3) and
XELOX (12.2% of PC3 - 14.9% of PC2) who suffered
from CINV tended to be more easily distinguished based on
fatigue interference. On the other hand, both factors man-
aged to distinguish CC in the AC-based population (9.8%
of PC4 - 13.4% of PC2) (Table 5).
Lastly, female gender was a more useful CINV predictor
for CRegs that incorporated heterogeneous populations, as
exemplified by the mixed male to female ratios in the HEC
and XELOX populations. This risk factor predicted patients
who did not achieve the clinical endpoints particularly in
acute phase CINV (16.2~17.7% of PC1) (Table 5). It sepa-
rated patients who did not achieve acute CR, CP and CC
from those who did, especially those on HECs (9.8% of
PC5 - 11.4% of PC4) and XELOX (11.9% of PC4 - 11.3%
of PC3). All these risk factors could potentially be used in
combination as clinical predictors of CINV in the support-
ive care of cancer patients.
DISCUSSION
This study utilized a multivariate projection technique to
identify a combination of risk factors that are useful in clini-
cal prediction of CINV. From our knowledge, this is the
first study that uses a computational technique to analyze
such a large combination of risk factors. The 5 clinical pre-
dictors identified here strengthen the evidence for CINV
prediction in Asian cancer patients. Females were previ-
ously reported to be more likely to suffer from post-chemo-
therapy NV (Abbrederis et al., 2009; Osoba et al., 1997),
and this was also identified as a useful predictor in our
study, particularly in “gender neutral” CRegs that are not
dominated by a particular gender. In fact, more males
seemed to achieve better overall CR and CP than females.
However, our study went a step further to show that gender
can also be used to predict patients who might not achieve
CC.
Fatigue has been reported as a predisposing factor to
post-chemotherapy nausea (Osoba et al., 1997), and also
contributes to the duration and frequency of acute vomiting
(Molassiotis et al., 2002). In this study, fatigue interference
was a better clinical predictor in patients on HECs and
XELOX, since it exhibited a higher priority role than sever-
ity in the PC analysis results. Although clinicians using
fatigue as a CINV predictor could base their assessments on
both interference and severity for AC-based populations,
fatigue interference might be more useful as a predictor for
patients on the other CRegs instead.
Histories of CINV accounted for relatively high percent-
age variances among all the clinical predictors. History of
vomiting was more predictive of patients who did not
achieve overall CR in HECs, and this result was consistent
with literature suggesting that chemotherapy-induced vomit-
ing may cause emesis in subsequent chemotherapies (Lohr,
2008; Navari and Province, 2006). On the other hand, dis-
tinguishing the endpoints through history of nausea was
supported by trials reporting that higher nausea severity was
experienced by non-chemo-naïve patients, and that nausea
control was adversely affected by prior CINV experience in
breast cancer patients (Abali and Celik, 2007; Gralla et al.,
2003). However, our study also extrapolated this result to
XELOX patients, thus adding to the already sparse litera-
ture on this CReg.
The PV approach used in this study has several advan-
tages over overall interpretation of the PCs (Al-Kandari and
Jolliffe, 2001). Some variables, such as anxiety and fatigue,
are difficult to measure due to their subjectivity, hence may
not accurately reflect the PC when an overall interpretation
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is made. Moreover, if there are many non-trivial loadings
on multiple variables, the PCs can be difficult to interpret,
in contrast to the variables themselves, which are usually
readily interpretable. In addition, eigenvectors (weightages)
were used instead of loadings (correlations) for interpreta-
tion of the PVs. Since the eigenvectors are proportional to
loadings in PC analysis, either vector can be used for data
interpretation (Dunteman, 1989). However, the purpose of
this study was to identify a subgroup of risk factors that
would be useful CINV predictors in the practice setting.
Thus, it was only logical that PVs, which represent the PCs,
were interpreted in relation to their weightages.
The main limitations of this study were its small sample
size, particularly of patients with head and neck cancers,
and the predominance of males and females in the head and
neck (79.1% males), and breast cancer (99.7% females)
populations. However, the gender ratios were representa-
tive of the respective cancer populations in Singapore (de
Kok et al., 2008; Lim, 2008; National Registry of Diseases
Office, 2009). Certain biases (recall and information bias)
could also have occurred due to the subjectivity of some
interview questions, such as those regarding fatigue and
anxiety. Furthermore, even though this research studied a
variety of CINV risk factors, there were others reported in
literature that were not being considered here because evi-
dences of these factors as CINV predictors have been scarce
(Booth et al., 2007; Dranitsaris et al., 2009; Molassiotis et
al., 2002; Osoba et al., 1997). Future work on the predic-
tion of CINV based on PC analysis and similar techniques
could target these factors, and should include larger sample
sizes to achieve approximate subject to variable ratios of
5 : 1 to 10 : 1. These sample sizes can be achieved by
involving a range of other cancer types and CRegs that are
moderately or highly emetogenic.
In summary, this study has utilized PC analysis, a multi-
variate projection technique, to distinguish the clinical end-
points of CR, CP and CC in patients with cancer having
certain risk factors. Five risk factors (histories of alcohol
drinking, chemotherapy-induced nausea, chemotherapy-induced
vomiting, fatigue, gender) have been identified as potential
clinical predictors of CINV that may be useful to practitio-
ners in cancer supportive care. This study not only illus-
trates the usefulness of PC analysis as a potential technique
in analyzing clinical population data for CINV, but also pro-
vides clinicians with an insight as to which clinical predic-
tors to look out for in Asian patients, so that appropriate
management can be taken to relieve the distress in patients
undergoing emetogenic chemotherapy, and ultimately, improve
their quality of life.
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